Endovenous Sildenafil Early Management in Newborns Pulmonary Hypertension
Status:
Not yet recruiting
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
Sildenafil is currently approved for the management of pulmonary hypertension of the newborn,
with the availability of intravenous presentation it has been seen that the severity
condition has already established, many times these patients do not have the adequate
clinical response and there are no studies to date that evaluate the efficacy and safety of
the same when it is started early in these patients, therefore we plan a randomized clinical
trial to determine the efficacy and safety of the administration of intravenous sildenafil
for early management of newborns with persistent pulmonary hypertension of the newborn.